Once-Daily Berotralstat Treatment for HAE Consistently Decre

These new data from BioCryst, presented at AAAAI, suggest that patients treated with berotralstat may see substantial decreases in HAE attacks.

Related Keywords

Washington , United States , France , American , Jonathan Bernstein , A Prospective Survey In Community Pharmacies , Bernstein Allergy Group Jonathan , University Of Cincinnati , Biocryst Pharmaceuticals Inc , American Academy Of Allergy , Bernstein Allergy Group , Cryst Pharmaceuticals , Berotralstat Prophylaxis Reduces , Rates Regardless , Baseline Attacks , Real World Outcomes , Berotralstat Regardless , Prior Prophylaxis , Real World Effectiveness , Inhibitor Deficiency , Hereditary Angioedema , Prospective Survey , Community Pharmacies , Long Term Prophylaxis , Berolife Study Interim Analysis , Angiodema , Hae , Berotralstat , Biocryst , Orladeyo ,